Long-term azithromycin therapy to reduce acute exacerbations in patients with severe chronic obstructive pulmonary disease

These data showed that long-term azithromycin reduces exacerbation numbers in severe COPD patients, and benefits persist beyond one year. Desirable effects are more likely to outweigh the risks and adverse events in patients colonized with Pseudomonas aeruginosa.